Sono-Immunotherapy for Tuberculosis: Targeting Granulomas to Prevent Recurrence

by Dr Natalie Singh - Health Editor
0 comments
  • Global Tuberculosis Report 2024 (World Health Organization, 2024).

  • van Doorn, C. L. R. et al. Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. EBioMedicine 82, 104173 (2022).

    Google Scholar

  • Helaine, S., Conlon, B. P., Davis, K. M. & Russell, D. G. Host stress drives tolerance and persistence: the bane of anti-microbial therapeutics. Cell Host Microbe 32, 852–862 (2024).

    Google Scholar

  • Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 12, 352–366 (2012).

    Google Scholar

  • Caño-Muñiz, S., Anthony, R., Niemann, S. & Alffenaar, J. C. New approaches and therapeutic options for Mycobacterium tuberculosis in a dormant state. Clin. Microbiol. Rev. 31, e00060–17 (2018).

  • van Rie, A. et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174–1179 (1999).

    Google Scholar

  • Verver, S. et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care Med. 171, 1430–1435 (2005).

    Google Scholar

  • Youn, H. M. et al. Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study. PLoS ONE 17, e0268290 (2022).

    Google Scholar

  • Abrahams, K. A. et al. DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid. Nat. Commun. 14, 3828 (2023).

    Google Scholar

  • Wallis, R. S., O’Garra, A., Sher, A. & Wack, A. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat. Rev. Immunol. 23, 121–133 (2023).

    Google Scholar

  • Vekemans, J. et al. Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: key considerations from World Health Organization consultations. Vaccine 38, 135–142 (2020).

    Google Scholar

  • Li, B. et al. Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles. Nat. Nanotechnol. 19, 834–845 (2024).

    Google Scholar

  • Wang, H. et al. NIR-II AIE luminogen-based erythrocyte-like nanoparticles with granuloma-targeting and self-oxygenation characteristics for combined phototherapy of tuberculosis. Adv. Mater. 36, 2406143 (2024).

    Google Scholar

  • Wang, W. et al. Biosafety materials for tuberculosis treatment. Biosaf. Health. 4, 258–268 (2022).

    Google Scholar

  • Suman, S. K., Chandrasekaran, N. & Priya Doss, C. G. Micro-nanoemulsion and nanoparticle-assisted drug delivery against drug-resistant tuberculosis: recent developments. Clin. Microbiol. Rev. 36, e0008823 (2023).

    Google Scholar

  • Wang, L. et al. Single-cell RNA-sequencing reveals heterogeneity and intercellular crosstalk in human tuberculosis lung. J. Infect. 87, 373–384 (2023).

    Google Scholar

  • Gideon, H. P. et al. Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control. Immunity 55, 827–846.e810 (2022).

    Google Scholar

  • Cliff, J. M. et al. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J. Infect. Dis. 213, 485–495 (2016).

    Google Scholar

  • Chai, Q., Wang, L., Liu, C. H. & Ge, B. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis. Cell. Mol. Immunol. 17, 901–913 (2020).

    Google Scholar

  • McCaffrey, E. F. et al. The immunoregulatory landscape of human tuberculosis granulomas. Nat. Immunol. 23, 318–329 (2022).

    Google Scholar

  • Nagai, Y. et al. Requirement for MD-1 in cell surface expression of RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 99, 1699–1705 (2002).

    Google Scholar

  • Zhuang, L., Yang, L., Li, L., Ye, Z. & Gong, W. Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention. MedComm 5, e419 (2024).

    Google Scholar

  • Hwang, A. A. et al. pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in mice. Small 11, 5066–5078 (2015).

    Google Scholar

  • Tiberi, S. et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect. Dis. 18, 183–198 (2018).

    Google Scholar

  • Piksa, M. et al. The role of the light source in antimicrobial photodynamic therapy. Chem. Soc. Rev. 52, 1697–1722 (2023).

    Google Scholar

  • Son, S. et al. Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem. Soc. Rev. 49, 3244–3261 (2020).

    Google Scholar

  • Ouyang, J. et al. Ultrasound mediated therapy: Recent progress and challenges in nanoscience. Nano Today 35, 100949 (2020).

    Google Scholar

  • Li, Y. et al. Nanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity. Nat. Commun. 14, 6973 (2023).

    Google Scholar

  • Li, J. et al. Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. Nat. Commun. 13, 4032 (2022).

    Google Scholar

  • Li, J. & Pu, K. Development of organic semiconducting materials for deep-tissue optical imaging, phototherapy and photoactivation. Chem. Soc. Rev. 48, 38–71 (2019).

    Google Scholar

  • Pu, K. et al. Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. Nat. Nanotechnol. 9, 233–239 (2014).

    Google Scholar

  • Tang, D. et al. Self-sacrificially degradable pseudo-semiconducting polymer nanoparticles that integrate NIR-II fluorescence bioimaging, photodynamic immunotherapy, and photo-activated chemotherapy. Adv. Mater. 34, e2203820 (2022).

    Google Scholar

  • Li, W., Liang, M., Qi, J. & Ding, D. Semiconducting polymers for cancer immunotherapy. Macromol. Rapid Commun. 44, e2300496 (2023).

    Google Scholar

  • Xu, C. et al. Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics. Nat. Biomed. Eng. 7, 298–312 (2023).

    Google Scholar

  • He, S. et al. A semiconducting iron-chelating nano-immunomodulator for specific and sensitized sono-metallo-immunotherapy of cancer. Angew. Chem. Int. Ed. Engl. 62, e202310178 (2023).

    Google Scholar

  • Li, F. et al. Organic semiconducting sono-metallo-detonated immunobombs for ultrasensitized domestication of immunosuppressive cells. Nano Lett. 24, 7340–7349 (2024).

    Google Scholar

  • Sparks, I. L. et al. Lipoarabinomannan mediates localized cell wall integrity during division in mycobacteria. Nat. Commun. 15, 2191 (2024).

    Google Scholar

  • Kang, P. B. et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp. Med. 202, 987–999 (2005).

    Google Scholar

  • Behr, M. A. B. C. G. different strains, different vaccines?. The Lancet Infect. Dis. 2, 86–92 (2002).

    Google Scholar

  • Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783–801 (2006).

    Google Scholar

  • Narayan, R. et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J. Investig. Dermatol. 132, 163–169 (2012).

    Google Scholar

  • Wang, Y. et al. Small-molecule modulators of toll-like receptors. Acc. Chem. Res. 53, 1046–1055 (2020).

    Google Scholar

  • West, A. P. et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476–480 (2011).

    Google Scholar

  • Panda, S. et al. Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection. Nat. Commun. 15, 765 (2024).

    Google Scholar

  • Musvosvi, M. et al. T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Nat. Med. 29, 258–269 (2023).

    Google Scholar

  • Liang, J. et al. Engineering versatile nanomedicines for ultrasonic tumor immunotherapy. Adv. Sci. 11, e2305392 (2024).

    Google Scholar

  • Rong, Z., Ertürk, A., Tang, Y. & Mai, H. Tissue clearing and its application in nanoparticle development. Small 21, 2410032 (2025).

    Google Scholar

  • Liu, T. et al. Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation. Sci. Rep. 6, 39473 (2016).

    Google Scholar

  • Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 17, 35–56 (2018).

    Google Scholar

  • Hermans, S. M. et al. High rates of recurrent tuberculosis disease: a population-level cohort study. Clin. Infect. Dis. 72, 1919–1926 (2021).

    Google Scholar

  • Panjabi, R., Comstock, G. W. & Golub, J. E. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int. J. Tuberc. Lung Dis. 11, 828–837 (2007).

    Google Scholar

  • Lambert, M. L. et al. Recurrence in tuberculosis: relapse or reinfection? The Lancet Infect. Dis. 3, 282–287 (2003).

    Google Scholar

  • Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365, 2155–2166 (2011).

    Google Scholar

  • Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41, 886–897 (2014).

    Google Scholar

  • Barnes, P. F. & Cave, M. D. Molecular epidemiology of tuberculosis. N. Engl. J. Med. 349, 1149–1156 (2003).

    Google Scholar

  • Chiang, C. Y. & Riley, L. W. Exogenous reinfection in tuberculosis. The Lancet Infect. Dis. 5, 629–636 (2005).

    Google Scholar

  • Wu, M. et al. Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity. Cell 187, 2935–2951.e19 (2024).

    Google Scholar

  • Lyashchenko, K. P., Vordermeier, H. M. & Waters, W. R. Memory B cells and tuberculosis. Vet. Immunol. Immunopathol. 221, 110016 (2020).

    Google Scholar

  • Hu, Z. et al. Extracellular vesicle-inspired therapeutic strategies for the COVID-19. Adv. Healthc. Mater. 13, e2402103 (2024).

    Google Scholar

  • Wang, W. et al. Antibiotic-loaded lactoferrin nanoparticles as a platform for enhanced infection therapy through targeted elimination of intracellular bacteria. Asian J. Pharm. Sci. 19, 100926 (2024).

  • Ouimet, M. et al. Mycobacterium tuberculosis induces the miR-33 locus to reprogram autophagy and host lipid metabolism. Nat. Immunol. 17, 677–686 (2016).

    Google Scholar

  • Wang, W. et al. Ultrastable in-situ silver nanoparticle dressing for effective prevention and treatment of wound infection in emergency. Eng. Regener. 5, 111–123 (2024).

    Google Scholar

  • date: 2026-02-10 19:56:00

    Related Posts

    Leave a Comment